Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,175.97 -23.72 -0.74%
FTSE 100 6,674.74 -7.02 -0.11%
DAX 9,544.19 -55.90 -0.58%
Ticker Volume Price Price Delta
NIKKEI 14,545.29 -0.98 -0.01%
TOPIX 1,173.11 -0.70 -0.06%
HANG SENG 22,527.38 17.74 0.08%

AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences



    AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences

PR Newswire

REDWOOD CITY, Calif., Feb. 27, 2013

REDWOOD CITY, Calif., Feb. 27, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that AcelRx will present a
corporate overview at the following two investor conferences in March 2013:

Cowen and Company 33^rd Annual Health Care Conference
Presenter: Richard King, President and CEO
Date: Wednesday, March 6, 2013 at 9:20 a.m. ET (6:20 a.m. PT)
Location: Boston Marriott Copley Place - Boston, Mass.

25^th Annual ROTH Conference
Presenter: James Welch, CFO
Date: Wednesday, March 20 at 10:30 a.m. PT (1:30 p.m. ET)
Location: The Ritz-Carlton, Laguna Niguel, Dana Point, CA

(Logo:  http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)

All presentations will be webcast live and can be accessed through the
investor relations page at www.acelrx.com.  For those not available to listen
to the live broadcast, a replay of the presentations will be archived and
available through www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain.  AcelRx's lead product candidate,
the Sufentanil NanoTab PCA System, which is currently in Phase 3 clinical
development, is designed to solve the problems associated with post-operative
intravenous patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine, the
invasive IV route of delivery and the complexity of infusion pumps.  AcelRx
has two additional product candidates which have completed Phase 2 clinical
development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03
for mild sedation, anxiety reduction and pain relief for patients undergoing
painful procedures in a physician's office.  AcelRx has completed enrollment
in a Phase 2 study for a fourth product candidate, ARX-04, a sufentanil
formulation for the treatment of moderate-to-severe acute pain, funded through
a grant from USAMRMC.  For additional information about AcelRx's clinical
programs please visit www.acelrx.com.

Forward Looking Statements
This press release contains forward-looking statements, including, but not
limited to, statements related to planned or anticipated future clinical
development of AcelRx Pharmaceuticals' product candidates, and the therapeutic
potential of AcelRx Pharmaceuticals' product candidates.  These
forward-looking statements are based on AcelRx Pharmaceuticals' current
expectations and inherently involve significant risks and uncertainties.
 AcelRx Pharmaceuticals' actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a
result of these risks and uncertainties, which include, without limitation,
risks related to: the success, cost and timing of AcelRx Pharmaceuticals'
product development activities and clinical trials; the market potential for
its product candidates; and other risks detailed in the "Risk Factors" and
elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission
filings, including its Current Report on Form 8-K filed with the SEC on
December 7, 2012.  AcelRx Pharmaceuticals undertakes no duty or obligation to
update any forward-looking statements contained in this release as a result of
new information, future events or changes in its expectations.

SOURCE AcelRx Pharmaceuticals, Inc.

Website: http://www.acelrx.com
Contact: Jim Welch, Chief Financial Officer, +1-650-216-3511,
jwelch@acelrx.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement